Abstract: Objective T o explore the efficacy of serum miR-1273g-3p levels in diagnosis of liver fibrosis in patients with chronic hepatitis C（CHC）. Methods 57 patients with CHC and 21 healthy persons were recruited in our hospital,and serum miR-1273g-3p were detected by real-time polymerase chain reaction. The patients with CHC received standardized peg-interferon-α2b and ribavirin therapy for 12 months,and received liver biopsies before and after the regimen. Results Serum miR-1273g-3p levels were（1.02±0.3） in 13 CHC patients with liver fibrosis 0（F0）,（1.68±0.26） in 20 with F 1-2,and（4.21±0.42） in 24 with F 3-4,respectively,which suggested serum miR-1273g-3p levels in patients with liver fibrosis were much higher than 【（1.03±0.2）,P<0.05】 in healthy persons or in patients without;at the end of the regimen,serum miR-1273g-3p levels in patients with CHC F0,F1-2 and F3-4 were（1.03±0.4）,（1.43±0.22） and （3.97±0.2）,respectively,much lower than those before anti-viral treatment （P<0.05）;the AUC of serum miR-1273g-3p levels in diagnosing liver fibrosis and significant liver fibrosis were 0.830,95％CI为0.714~0.973 （sensitivity 72.2％ and specificity 86.4％）,and were 0.864,95％CI为0.701~0.976 （sensitivity 83.6％ and specificity 78.4％,as the cut-off-value were >1.68 and >4.20,respectively;at discontinuation of the regimen,the liver histological examination showed that the liver fibrosis was F0 in 15,F1 in 9,F2 in 14,F3 in 11 and F4 in 8. Conclusion s Serum miR-1273g-3p levels might be used to diagnose liver fibrosis in patients with CHC,which warrants further investigation.

Key words: Hepatitis C, miR-1273g-3p, Liver fibrosis, Diagnosis